HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT03854578

A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions

Medication studyAges 18–45Germany
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 45 years.

Listed locations
BerlinSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study clarity

Study information

Study start dateStarted: March 12, 2019
Recruitment status
Completed
Enrollment listed in the registry
73
Sponsor
Boehringer Ingelheim
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
Germany
Age range
From 18 Years to 45 Years
Official registry ID
NCT03854578
Official title
Show the full official title

A Single Dose, Randomized, Placebo Controlled Phase I Study on the Effects of BI 1358894 on Functional MRI Measurements in an Emotional Processing Paradigm in Patients With Major Depressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Berlin

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Boehringer Ingelheim.

Did this study involve medication?

Yes. The study involved medication, including BI 1358894, Placebo matching BI 1358894 and Citalopram.

Who was this study for?

Listed age limits: 18 years to 45 years.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me